Abstract-Aging is associated with the progression of arteriosclerosis and the decline of several endocrine functions. We therefore investigated the association of coronary arteriosclerosis with hormones, the serum concentrations of which change during aging. Coronary angiograms of 189 men Ͻ70 years old were evaluated by 3 semiquantitative score systems to estimate the extent of focal and diffuse vessel wall alterations. Fasting sera were analyzed for levels of glucose, lipids, thyroid-stimulating hormone, insulin, insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), dehydroepiandrosterone sulfate (DHEAS), testosterone, and sex hormone-binding globulin (SHBG). After adjustment for age, body mass index, and waist-to-hip ratio, 92 patients with Ն1 stenoses Ͼ70% differed from 97 patients without such focal lesions by higher serum levels of glucose, total and LDL cholesterol, and apolipoprotein (apo) B, as well as by lower serum levels of IGFBP-3. Multivariate analyses revealed significant and independent correlations of all 3 coronary scores with LDL cholesterol (or apoB) and IGFBP-3; of 2 coronary scores with age, glucose, and insulin; and of 1 score with IGF-I. No significant correlations existed for waist-to-hip ratio (or body mass index) and DHEAS (or testosterone or SHBG). IGFBP-3 explained 9% to 14% and 3.5% to 10% of the variances of focal and diffuse lesions, respectively. In conclusion, IGFBP-3 and, with much less strength and consistency, insulin and IGF-I, but not markers of hypothyroidism, adrenopause, and andropause, have statistically significant and independent associations with coronary arteriosclerosis in men. ging is characterized by a gradual decrease of many biological functions. Thus, the progression of atherosclerosis is preceded and paralleled by the impairment or loss of function in other general physiological systems of the organism, for example, the endocrine system. 1 The endocrinology of aging is characterized by the increased prevalence of autoimmune thyroiditis and decreased conversion of thyroxin into triiodothyronine, which result in thyroid dysfunction; by insulin resistance and ␤-cell failure, which result in glucose intolerance; by somatopause, with decreasing serum levels of growth hormone and insulin-like growth factor I (IGF-I); and by adrenopause, with declining serum levels of dehydroepiandrosterone sulfate (DHEAS). In addition, menopause leads to the loss of estrogens in women and andropause to the decrease of testosterone serum levels in Ϸ50% of men Ͼ60 years old. 1 Insulin resistance and insulin deficiency contribute to the manifestation and progression of coronary arteriosclerosis both directly and through their metabolic sequelae, eg, diabetes mellitus, hypertension, and dyslipidemia. 2,3 The protective effects of estrogens on the biology of vascular cells and the clinical course of atherosclerotic vessel disease in women have been documented in great detail. 4, 5 Much less is known about the relationships between arteriosclerosis and testosterone, DHEAS, or the growth hormone/IGF-I axis. Serum levels of testosterone and DHEAS were found to have significant associations with the incidence or presence of coronary heart disease, which, however, were related inversely in men and positively in women. 6,7 Animal studies and in vitro studies have also yielded contradictory results on the role of androgens in arteriosclerosis. 6, 7 Several clinical studies have reported associations of growth hormone deficiency as well as of low serum levels of (free) IGF-I with premature coronary heart disease. 8 -12 However, growth hormone deficiency and low serum levels of IGF-I, high serum levels of thyroid-stimulating hormone (TSH) as an indicator of (latent) hypothyroidism, and low serum levels of testosterone or DHEAS in men or high serum levels of these androgens in women are confounded by various metabolic disorders, including obesity, insulin resistance, dyslipidemia, and impaired fibrinolysis.
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Methods

Subjects
A total of 189 men Ͻ70 years old (54.7Ϯ11.1 years) were selected out of 2346 consecutive patients who underwent coronary angiography or percutaneous transluminal coronary angiography (PTCA). 15 Selection criteria were (1) first coronary angiography or PTCA and (2) the absence of any lipid-lowering therapy. Indications to undergo coronary angiography were either verification of coronary heart disease (77%) in patients with angina pectoris, previous myocardial infarction older than 2 months, abnormal exercise or thallium tests, or planned first PTCA, or exclusion of coronary artery disease (23%) in patients with other cardiac diseases. These indications and exclusion criteria have been described in detail previously. 15 
Anthropometric Data
Body height was measured in centimeters with a statometer. For the determination of body weight, the probands were dressed only in underwear. Body mass index (BMI) was calculated as the ratio of weight (kg) to the square of height (m 2 ). The circumferences of waist and hip were measured in millimeters at the level of the umbilicus and at the largest circumference at the buttocks, respectively. Waist-to-hip ratio (WHR) was calculated by division of the 2 parameters.
Coronary Angiography
The cine films were evaluated independently by 2 cardiologists blinded to the patients' clinical or laboratory findings. The evaluation included 3 different scoring systems, as follows. 15 
Vessel Score
Vessel score was 0 to 3 points. Each of the main coronary arterial branches (left anterior descending, left circumflex artery, right coronary artery) having Ն1 stenoses of Ն70% was given 1 point each. If the left main stem, which was regarded as 1 vessel, and the left anterior descending and/or the left circumflex artery were affected, this was counted as 2 points.
Stenosis Score
Stenosis score was 0 to 32 points. The maximum diameter reduction of 8 coronary segments (left main stem, left anterior descending artery, main diagonal branch, main septal branch, left circumflex artery, main marginal branch, right coronary artery, right posterior descending branch) was scored with 1 to 4 points according to a luminal narrowing of 1% to 49% (1 point), 50% to 74% (2 points), 75% to 99% (3 points), or a total occlusion (4 points).
Extent Score
Extent score was 0 to 100 points. This score was developed by Sullivan et al. 16 According to the proportional length of each vessel segment in the coronary artery tree, segments were graded with different maximum numbers of points: 5 points for the left main stem, 20 for the left anterior descending artery, 10 for the main diagonal branch, 5 for the first septal branch, 20 for the left circumflex artery, 10 for the obtuse marginal and posterolateral vessels, 20 for the right coronary artery, and 10 for the right posterior descending branch. The number of points for each segment (irrespective of the degree of diameter reduction) was expressed as the percentage length of visible lesions within the total segment. Occluded vessels that were filled with contrast medium by collateral flow were scored according to the visible irregularities of the vessel wall. If no collateral flow existed, the mean value of all other vessel segments of this angiogram was given to this occluded vessel segment.
Sample Collection
Blood was taken after 12 to 14 hours of fasting in the morning and before coronary angiography. Sera were obtained after Ն30 minutes of clotting by centrifugation at 2000g for 15 minutes. Sera were removed and either used directly for the measurements of metabolic parameters and TSH or frozen at Ϫ70°C for later determination of other endocrinological parameters within the series.
Measurements of Metabolic Parameters
Serum levels of glucose, total cholesterol, triglycerides, and HDL cholesterol (HDL-C) were determined by enzymatic tests (Roche Diagnostics). HDL-C was determined after precipitation of apoBcontaining lipoproteins with phosphotungstic acid/MgCl 2 . LDL cholesterol (LDL-C) was calculated by the Friedewald formula. 17 Apolipoproteins A-I (apoA-I) and B (apoB) were measured with turbidimetric immunoassays from Roche Diagnostics, and lipoprotein(a) [Lp(a)] with a latex-enhanced turbidimetric immunoassay from Immuno. All measurements were performed with the Hitachi 917 Autoanalyzer (Roche Diagnostics). Interassay imprecisions were Ͻ5% for all tests.
Measurements of Hormones
Serum levels of insulin and insulin-like growth factor-binding protein-3 (IGFBP-3) were determined by use of microtiter plate enzyme immunoassays from Dako and Diagnostic Systems Laboratories Inc, respectively. These hormone measurements were done in duplicate, and results were accepted if the coefficients of variation were Ͻ10%. Automated chemiluminescence immunoassays were used for the quantification of IGF-I and DHEAS (Advantage from Nichols Diagnostics), testosterone and TSH (ACS 180 from Chiron diagnostics), and sex hormone-binding globulin (SHBG) (Immulite system from DPC Biermann GmbH). Interassay coefficients of variation of the latter hormone measurements were Ͻ10%.
Statistics
An exploratory analysis was performed with the Statistical Package for the Social Sciences (SPSS-X). 18 Comparisons of mean values between patients with coronary arteriosclerosis (vessel, stenosis, or extent scoreϾ0) and patients without coronary arteriosclerosis (vessel, stenosis, or extent scoreϭ0) were done by t test. This analysis was performed on unadjusted data and on data that were adjusted for age, BMI, and WHR by standardization for the median of the respective parameters. Univariate regression analyses were performed according to Pearson. Multiple regression analyses were performed only on parameters that on univariate analysis had significant correlations with Ն1 vessel score. All indicated parameters were entered simultaneously into the various models. The variance in arteriosclerotic lesions explained by the various multivariate models and the various parameters within the model was estimated by R 2 and the square of the correlation coefficient ␤, respectively. For some parameters [triglycerides, Lp(a), insulin, IGF-I, testosterone, SHBG, testosterone/SHBG ratio, DHEAS, TSH], logarithmic (log e ) transformation was necessary to obtain a Gaussian frequency distribution, which is mandatory for these parametric tests.
Results
Association of Metabolic Risk Factors and Hormones With the Presence of Coronary Arteriosclerosis
Tables I and II compare the mean values of anthropometric parameters, metabolic risk factors, and hormones in patients with and without angiographically detectable coronary arteriosclerosis. Absence of coronary arteriosclerosis was defined either as the absence of stenoses Ͼ70% in the main coronary arterial branches, ie, vessel scoreϭ0 (Table I) or as the absence of any diameter reduction or diffuse lesion in the 8 coronary segments, ie, stenoses and extent scoreϭ0 (Table  II) . In both scoring systems, patients with angiographically detectable coronary arteriosclerosis were characterized by significantly higher age (PϽ0.001) and higher serum levels of glucose (PϽ0.001 and PϽ0.05), total (PϽ0.001 and PϽ0.05) and LDL (PϽ0.001) cholesterol, and apoB (PϽ0.01), as well as by lower serum levels of IGFBP-3 (PϽ0.001 and PϽ0.01) (Tables I and II) . In addition, the presence of focal lesions, ie, vessel score 1, 2, or 3, was associated with significantly higher BMI (PϽ0.05), and lower level of DHEAS (PϽ0.01) ( Table I ) and presence of diffuse lesions, ie, stenoses and extent scores Ͼ0, were also associated with significantly higher WHR and significantly lower apoA-I (PϽ0.05) and IGF-I (PϽ0.05) levels (Table II) . After adjustment for age, BMI, and WHR, the differences in glucose, cholesterol, LDL-C, apoB (all scores), apoA-I (stenoses and extent scores), and IGFBP-3 (vessel score) remained significant. Tables III and IV show the results of a multiple regression analysis of relationships between coronary scores and potential risk factors. In these models, only those parameters were considered that had significant associations with the presence of focal or diffuse arteriosclerotic lesions (Tables I and II) or had significant bivariate correlations with Ն1 vessel scores (not shown). In some cases, Ն2 parameters that are functionally related and therefore strongly correlated with one another had significant associations with the presence of angiographically detectable lesions or correlations with coronary scores, eg, BMI and WHR, HDL-C and apoA-I, and LDL-C and apoB. In these cases, we entered only 1 variable. We primarily tested a model that encompassed the variables age, WHR, glucose, LDL-C, HDL-C, insulin, IGF-I, IGFBP-3, and DHEAS (Table III) . This model explained 28% to 32% of the variation in coronary scores. LDL-C and IGFBP-3 had significant correlations with all 3 vessel scores. Age and glucose had significant correlations to the stenosis and extent scores. Multivariate correlations between insulin and vessel score or stenosis score were also statistically significant (PϽ0.05). In this model, IGFBP-3 explained 9.2%, insulin 2.8%, and LDL-C 7.3% of the variance in focal lesions. The variances in diffuse lesions explained by IGFBP-3, insulin, and LDL-C were 3.5% to 5.7%, 1.6% to 2.9%, and 6.0% to 8.9%, respectively.
Correlations Between Coronary Scores and Clinical and Laboratory Findings
When apoB and apoA-I were entered into the multiple regression model instead of LDL-C and HDL-C, respectively, the models also explained Ϸ30% of the variation in coronary vessel scores (Table IV) . The correlations of apoB to the coronary scores tended to be stronger than the correlations of LDL-C. Moreover, and interestingly, in this model compared with the previous model, the correlations of coronary scores with IGFBP-3 became stronger and the correlations of coronary scores with glucose and insulin became weaker (Tables  III and IV ). In this model, IGFBP-3 explained 13.8%, insulin 1.8%, and apoB 7.8% of the variance in focal lesions. The same parameters accounted for 6.0% to 9.9%, 1.0% to 1.8%, and 6.8% to 9.5% of the variances in diffuse lesions, respectively.
IGF-I had no or only borderline statistically significant correlations with any coronary score. These correlations did not become stronger when IGFBP-3 was omitted from the models. Conversely, however, IGFBP-3 kept most of its statistically significant correlations when IGF-I was omitted. In none of these models did HDL-C, apoA-I, WHR, or DHEAS show significant and independent correlations to any coronary score. Likewise, neither BMI nor testosterone (nor SHBG nor testosterone ratio) had significant correlations with any vessel score when entered instead of WHR or DHEAS, respectively.
Discussion
Interindividual variability in the decay of various endocrine functions may contribute to differences in the clinical onset and further progression of arteriosclerosis, either directly by the regulation of vascular functions or indirectly through the interaction with risk factors. To unravel the role of various endocrine systems in arteriosclerosis whose function is reduced by aging, we investigated the relationships between the presence or severity of coronary arteriosclerosis and various hormones or conventional risk factors in 189 men Ͻ70 years old.
IGFBP-3 was the only endocrine parameter that on adjusted and multivariate statistical analyses consistently had significant associations with the presence and extent of coronary arteriosclerosis. On multivariate regression analyses, IGFBP-3 had significant correlations with both the number of focal lesions (vessel score), the number of diffuse lesions (stenoses score), and the extent of diffuse lesions (extent score), which were independent of age, BMI or WHR, LDL-C or apoB, HDL-C or apoA-I, and insulin or glucose, as well as DHEAS, SHBG, or testosterone (Tables III and IV) . IGFBP-3 explained 9% to 14% of the variance in focal lesions and 3.5% to 10% of the variance in diffuse lesions, compared with 7% to 8% and 6% to 10%, respectively, explained by LDL-C or apoB, and 2% to 3% and 1% to 3%, respectively, explained by insulin (Tables III and IV) .
What is the physiological basis of the associations between IGFBP-3 and the presence and extent of coronary arteriosclerosis? The association may be causal and reflect an involvement of the somatotropic axis in the pathogenesis of arteriosclerosis but may also be a surrogate for the actions of other factors that affect both IGFBP-3 serum levels and arteriosclerosis, for example, insulin resistance, obesity, and sex hormones. Finally, arteriosclerosis itself may influence IGFBP-3 levels. IGFBP-3 is one of Ն7 binding proteins that prolong the half-life of IGF-I and IGF-II in plasma and that modulate the interaction of IGFs with their receptors on target cells and thereby their mitogenic and metabolic actions. 19, 20, 21 IGFBP-3 accounts for Ϸ75% of the circulating IGFBPs and transports 70% to 90% of IGF-I. 19 IGFBP-3 inhibits cell growth, both directly by inhibition of DNA synthesis and indirectly by sequestration of IGFs, which stimulate cell growth. 19, 20, 21 To the best of our knowledge, no data on direct interactions of IGFBP-3 with vascular cells have been reported. However, one of its ligands, IGF-I, was shown to stimulate the proliferation of arterial smooth muscle cells if present at low concentrations and to inhibit smooth muscle cell proliferation if present at high concentrations. 22, 23 Moreover, IGF-I stimulates nitric oxide production in both smooth muscle cells and endothelial cells. 24 Thus, IGF-I exhibits both proatherogenic and antiatherogenic properties. In agreement with an antiatherogenic effect of IGF-I, we (this study) and other researchers found inverse associations between IGF-I and free IGF-I with coronary heart disease 8, 10 and premature arteriosclerosis in growth hormone-deficient hypophysectomized patients. 11, 12 However, it is important to note that in our study, most of the associations and bivariate correlations (not shown) of IGF-I lost their statistical significance after adjustment for age and obesity (Tables I and II) and on multivariate analysis (Tables III and IV) . Moreover, because IGFBP-3 sequesters bioactive free IGF-I, the inverse association of IGFBP-3 with arteriosclerosis also at first sight argues against antiatherogenic actions of IGF-I. However, high levels of IGFBP-3 in serum may also reflect a large pool of bound IGF-I that can be released by proteases within the arterial wall. [25] [26] [27] It will hence be interesting to study the direct effects of both IGF-I and IGFBP-3 on vascular cells. Alternatively, because both IGF-I and IGFBP-3 serum levels correlate with growth hormone secretion and because growth hormone exerts some of its actions independently of IGF-I, 19, 20, 21 the inverse association of both IGF-I and IGFBP-3 may reflect the involvement of this hormone in arteriosclerosis. Unfortunately, the pulsatile secretion of growth hormone does not allow us to test this hypothesis directly by the measurement of growth hormone serum levels. In this context, it is noteworthy that growth hormone exerts beneficial effects on some cardiovascular risk factors independently of IGF-I, for example, lowering LDL-C and Lp(a) and increasing HDL-C. 13,14,28 -30 IGFBP-3 concentration is also regulated by proteolytic cleavage, which in turn is regulated by insulin. 19, [25] [26] [27] For example, proteolysis of IGFBP-3 was found to be increased in patients with type 2 diabetes. 31 Thus, low IGFBP-3 in coronary heart disease patients may reflect insulin resistance. In our study, however, insulin levels did not correlate with IGFBP-3 (not shown), and multivariate correlations of IGFBP-3 with the extent of coronary arteriosclerosis were stronger than and independent of insulin (Tables III and IV) . IGFBP-3 had inverse correlations with BMI, WHR, and glucose (not shown), which may indicate the relationship of IGFBP-3 with insulin resistance. Nevertheless, the association of IGFBP-3 with the presence of disease (Tables I and II) and its correlations with the 3 coronary scores were independent of measures of obesity and glucose (Tables III and IV) . It is important to note, however, that the strength of correlations between the 3 coronary scores and glucose or insulin on the one hand and IGFBP-3 on the other hand varied at mutual expense. This may be a subtle indication that low IGFBP-3 levels are part of the insulin resistance cluster, which contributes to arteriosclerosis.
Finally, some of the proteases that degrade IGFBP-3 are also secreted by macrophages, eg, metalloproteinases. 19, 26 It is hence important to consider that low IGFBP-3 may simply indicate the presence of vascular disease.
Insulin and/or glucose also had significant and independent associations with various coronary scores. These relationships are in agreement with the previously demonstrated associations of glucose intolerance/diabetes mellitus and insulin resistance/hyperinsulinemia with coronary arteriosclerosis. 2, 3, 32 Traditionally, these associations have been explained with the manifestation of a proatherogenic risk factor profile in many glucose-intolerant and insulin-resistant patients. 32 In our study, however, several components of the insulin resistance syndrome, ie, obesity, triglycerides, and blood pressure, had no significant or independent associations with coronary arteriosclerosis. Moreover, the correlations of insulin and glucose with the severity of coronary arteriosclerosis were independent of HDL-C or apoA-I. Thus, it appears that fasting insulin and glucose are more specific markers of the atherogenic metabolic syndrome and/or reflect direct interactions with the atherosclerotic process. In this context, it is also important to note that insulin exerts several direct effects on vascular wall cells, eg, induction of nitric oxide release from endothelial cells and stimulation of ion pumps in smooth muscle cells, resulting in endothelium-dependent and -independent vasodilation, respectively. 2, 3 On univariate analysis, we confirmed inverse associations between DHEAS and the presence and extent of coronary arteriosclerosis ( Table I ) that were also assessed in several previous studies. 6, 7 However, these associations were not stable after adjustment for confounders (age, obesity) and on multivariate analysis, probably because of the correlations of DHEAS with age, glucose, IGF-I, IGFBP-3, and LDL-C. Also in other studies, DHEAS was confounded with components of the metabolic syndrome so that its role as an independent cardiovascular risk factor is questionable. 6, 7 Likewise, it is important to note that neither testosterone nor the testosterone/SHBG ratio as a surrogate marker for free and bioactive testosterone levels had significant associations, which have been found in some previous studies. 6, 7, 33 In conclusion, IGFBP-3 and, with much less strength and consistency, insulin and IGF-I, but not markers of hypothyroidism, adrenopause, and andropause, have statistically significant and independent associations with coronary arteriosclerosis in men.
